Background/Objectives: The direct bridge to urgent heart transplant (HT) with venoarterial extracorporeal membrane oxygenation (VA-ECMO) support has been associated with high morbidity and mortality. The objective of this study is to analyze the morbidity and mortality of patients transplanted with VA-ECMO and compare the presumed differences between various eras over a 17-year timeline. Methods: This is a prospective, observational study on consecutive patients stabilized with VA-ECMO and transplanted with VA-ECMO from July 2007 to December 2023 at a reference center (98 patients). Objective variables were mortality and morbidity from renal failure, venous thromboembolic disease (VTD), primary graft dysfunction (PGD), the need for tracheostomy, severe myopathy, reoperation, post-transplant ECMO, vascular complications, and sepsis/infection. Results: The percentage of patients who reached transplantation without the need for mechanical ventilation has increased over the periods studied. No significant differences were found between the study periods in 30-day mortality (p = 0.822), hospital discharge (p = 0.972), one-year mortality (p = 0.706), or five-year mortality (p = 0.797). Survival rates in these periods were 84%, 75%, 64%, and 61%, respectively. Comorbidities were very frequent, with an average of 3.33 comorbidities per patient. The most frequent were vascular complications (58%), the need for post-transplant ECMO (57%), and myopathy (55%). The development of myopathy and the need for post-transplant ECMO were higher in recent periods (p = 0.004 and p = 0.0001, respectively). Conclusions: VA-ECMO support as a bridge to HT allows hospital discharge for 3 out of 4 transplanted patients. This survival rate has not changed over the years. The comorbidities associated with this device are frequent and significant.
22 April 2022 in Revista Española de Quimioterapia
Background/Objectives: This study evaluates the outcomes of extracorporeal membrane oxygenation (ECMO), in venoarterial configuration, and short-term ventricular assist devices (VADs) used as a bridge to heart transplantation (HT). The primary objective was to identify predictors of in-hospital mortality among patients on the urgent HT waiting list receiving short-term mechanical circulatory support, including direct ECMO-to-HT, direct short-term VAD-to-HT, and ECMO as a bridge to short-term VAD followed by HT (ECMO bridge-to-bridge). Secondary objectives included identifying predictors of in-hospital mortality in transplanted patients and assessing their long-term survival. Methods: A single-center, retrospective, observational, and analytical study conducted at a tertiary care hospital, including patients supported with ECMO and short-term VAD support as a bridge to HT between 2007 and 2024. Results: A total of 183 patients were included: 110 in the ECMO-to-HT group, 51 in the VAD-to-HT group, and 22 in the ECMO bridge-to-bridge group. Among them, 147 underwent HT (80.3%). Overall in-hospital mortality was 37.2% (115 of 183 patients survived), while in-hospital mortality among transplanted patients was 21.8% (115 of 147 survived). Independent predictors of in-hospital mortality included infection, ECMO bridge-to-bridge strategy, higher body mass index (BMI), older age, and neurological complications. In the transplanted subgroup, predictors of both in-hospital and long-term mortality were ECMO support and older recipient age. Notably, a donor BMI exceeding that of the recipient by more than 10% was associated with improved survival. Conclusions: The complexity of patients requiring mechanical circulatory support and the physiological effects of different devices necessitate early, individualized management based on the etiology of cardiogenic shock and urgency status.